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Protocol
AbstrACt
Introduction Chronic inflammatory diseases (CIDs) are 
frequently treated with biological medications, specifically 
tumour necrosis factor inhibitors (TNFi)). These medications 
inhibit the pro-inflammatory molecule TNF alpha, which 
has been strongly implicated in the aetiology of these 
diseases. Up to one-third of patients do not, however, 
respond to biologics, and lifestyle factors are assumed 
to affect treatment outcomes. Little is known about the 
effects of dietary lifestyle as a prognostic factor that may 
enable personalised medicine. The primary outcome of this 
multidisciplinary collaborative study will be to identify dietary 
lifestyle factors that support optimal treatment outcomes.
Methods and analysis This prospective cohort study 
will enrol 320 patients with CID who are prescribed a TNFi 
between June 2017 and March 2019. Included among the 
patients with CID will be patients with inflammatory bowel 
disease (Crohn’s disease and ulcerative colitis), rheumatic 
disorders (rheumatoid arthritis, axial spondyloarthritis, 
psoriatic arthritis), inflammatory skin diseases (psoriasis, 
hidradenitis suppurativa) and non-infectious uveitis. At 
baseline (pretreatment), patient characteristics will be 
assessed using patient-reported outcome measures, clinical 
assessments of disease activity, quality of life and lifestyle, 
in addition to registry data on comorbidity and concomitant 
medication(s). In accordance with current Danish standards, 
follow-up will be conducted 14–16 weeks after treatment 
initiation. For each disease, evaluation of successful 
treatment response will be based on established primary 
and secondary endpoints, including disease-specific core 
outcome sets. The major outcome of the analyses will be to 
detect variability in treatment effectiveness between patients 
with different lifestyle characteristics.
Ethics and dissemination The principle goal of this project 
is to improve the quality of life of patients suffering from CID 
by providing evidence to support dietary and other lifestyle 
recommendations that may improve clinical outcomes. The 
study is approved by the Ethics Committee (S-20160124) 
and the Danish Data Protecting Agency (2008-58-035). 
Study findings will be disseminated through peer-reviewed 
journals, patient associations and presentations at 
international conferences.
trial registration number NCT03173144; Pre-results.
strengths and limitations of this study
 ► This study includes a number of diseases treated 
with biologics, targeting the pro-inflammatory 
cytokine tumour necrosis factor alpha.
 ► All evaluations will be performed as part of 
a prospectively designed cohort study using 
established disease-specific scoring systems.
 ► As comparisons between diseases are limited 
by disease-specific scoring systems, additional 
response criteria (eg, quality of life and disability) 
will be used for analysis.
 ► The sample size is limited.
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IntroduCtIon 
Chronic inflammatory diseases (CIDs) are a diverse set 
of immunological diseases that include inflammatory 
bowel disease (IBD) (Crohn’s disease (CD) and ulcer-
ative colitis (UC)), rheumatic conditions (rheumatoid 
arthritis (RA), axial spondyloarthropathy (axSpA), psori-
atic arthritis (PsA)), inflammatory skin diseases (psoriasis 
(PsO), hidradenitis suppurativa (HS)) and eye disease 
(non-infectious uveitis (NiU)). The pro-inflammatory 
cytokine tumour necrosis factor α (TNF) is recognised to 
play an important role in the aetiology of these diseases. 
Correspondingly, biological agents that inhibit TNF, 
also known as TNF inhibitors (TNFi), are an important 
component of treatment. However, a large number of 
patients do not benefit from TNFi treatment.1 
CIDs have a large and negative impact on both indi-
vidual patients and at a community level as a conse-
quence of health-related workplace productivity loss and 
health system expense, which is largely influenced by 
the high cost of providing biological medications.1 CIDs 
are recurring, lifelong illnesses of potentially early onset 
that can substantially affect the life quality of patients 
and their families.2–5 In addition, they are prevalent 
diseases with IBD affecting 0.5% of the population in the 
Western world,6 and RA and PsO affecting respectively 
0.3%–1.0% and 1.5% of the global population.7 8 Further-
more, the disease burden, and hence health system 
burden, is predicted to rise dramatically due to popula-
tion growth, ageing demographics and increasing disease 
incidence.9–11
The diseases may have overlapping symptoms.12 For 
example, some patients with NiU and axSpA may expe-
rience bowel symptoms, and some patients with IBD may 
develop extraintestinal manifestations (ie, eye, joint and 
skin symptoms). The diseases are rather complex with 
both genetic and environmental factors implicated in 
aetiology. While CIDs share some genetic and environ-
mental predisposing factors, other susceptibility factors 
differ.13 The genetic architecture of CIDs has previously 
been investigated by large international consortia.14–20 
Similarly, environmental factors have been investigated 
in large cohorts with prospectively collected lifestyle 
data, such as the European Investigation into Cancer and 
Nutrition Study as well as the Nurses’ Health Study.21–35
In light of the notable impact that environment factors 
play in disease development, which is further supported 
by the increasing incidence of these disease,6 11 it stands 
to reason that modifying environment factors such as 
lifestyle may influence treatment response. Accordingly, 
quite a few patients ask their healthcare professionals for 
lifestyle recommendations that can influence the effec-
tiveness of treatment, and in particular the outcomes 
achieved with TNFi.
Evidence-based research
In an attempt to increase value and reduce waste in 
research, a systematic review of existing evidence was 
performed prior to embarking on this study.36 In a recent 
systematic review examining the impact of diet on TNFi 
response in IBD,37 it was concluded that there is scarce 
evidence linking TNFi treatment response to specific 
dietary recommendations; hence, there is a clear research 
need. Similarly, only a few large prospective studies have 
assessed the effects of lifestyle on TNFi-treated patients 
with CID.38 One prospective study compared partial 
enteral nutrition (16 patients), exclusive enteral nutri-
tion (22 patients) and TNFi (52 patients) therapy in 90 
paediatric patients. There were no significant differences 
in clinical response rates between the three treatment 
arms, although the rate of patients that achieved a faecal 
calprotectin concentration of ≤250 µg/g was higher 
among the TNFi-treated patients.39
More recently, lifestyle factors, as they relate to TNFi 
therapy among patients with CID, were identified as an 
area for further investigation.40 To explore different 
hypotheses, we included studies that may be subject to 
recall bias or bias introduced by lifestyle changes due to 
the disease itself, for example, smoking, physical activities 
and intake of Western-style diet.40 After reviewing these 
potential hypotheses, we proposed a model, whereby a 
diet high in meat and low in fibres may impact inflamma-
tion and TNFi treatment37 (figure 1).
Based on previous evidence, we set out to prospectively 
identify dietary factors that support optimal TNFi treat-
ment outcomes, with the ultimate aim of improving the 
quality of life of patients with CID.
Aims and hypotheses
The primary aim of this prospective cohort study is to 
investigate whether treatment outcomes in patients with 
CID vary with dietary differences. The main hypothesis 
is that ‘Diets high in fibre AND low in red and processed 
meat are associated with improved treatment outcomes’. 
Secondary aims are whether and to what extent life-
style-associated biomarkers have prognostic value for 
differentiating responders from non-responders based 
on both disease-specific and generic treatment outcomes.
MEthods And AnAlysEs
design
This study is a prospective cohort study that will 
examine disease activity after initiating TNFi treatment. 
The primary endpoint will be assessed 14–16 weeks 
after initiation of a TNFi and will be defined based on 
the specific CID condition. The cohort will be classi-
fied as responders (including those who continue 
with drug treatment) or non-responders (including 
those who discontinue drug treatment) based on the 
disease-specific criteria defined below. The decision to 
discontinue therapy is assumed to be based on a shared 
decision-making process between patients and their 
physicians and to be supported by principles outlined 
in disease-specific guidelines.41
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setting
This multicentre study reflects a collaboration between 
the following centres: (1) Department of Gastroenter-
ology and Hepatology, Aalborg University Hospital; (2) 
Department of Hepatology and Gastroenterology, Aarhus 
University Hospital; (3) Diagnostic Centre, Silkeborg 
Regional Hospital; (4) Department of Internal Medicine, 
Herning Regional Hospital; (5) Department of Gastro-
enterology, Herlev Hospital; (6) Organ Centre, Hospital 
of Southern Jutland; (7) Department of Gastroenter-
ology, Hospital of South West Jutland; (8) Department 
of Medical Gastroenterology, Department of Rheuma-
tology, Department of Dermatology and Allergy Centre 
and Department of Ophthalmology, Odense University 
Hospital. Study enrolment will take place between 15 June 
2017 and 31 March 2019 or until the study has enrolled a 
minimum of 100 patients with IBD, 100 patients with RA 
and 120 patients with axSpA, PsA, PsO, HS and NiU.
Figure 1 Hypothesis for effects of diet in relation to treatment effect. (Left) Low levels of fibre intake may promote microbial 
metabolism of mucus as the main energy source.37 75 76 This will lead to decrease of the mucus layer. Further, degradation of 
mucus releases free sulfate, which would then become available for use by sulfate-reducing bacteria (eg, Bilophila wadsworthia) 
for microbial produced hydrogen sulfide.77 In addition, high intake of food containing organic sulfur and sulfate additives, such 
as meat and processed meat, may increase the amount of sulfate for microbial produced hydrogen sulfide.78 79 The resultant 
hydrogen sulfide from low intake of fibre and high intake of meat may reduce the disulfide bonds in the mucus network 
rendering the mucus layer penetrable to, for example, bacteria.77 80 Then, MAMPs from microbes or contained in the diet may 
reach the epithelium and activate the pattern recognition receptors such as TLRs on the enterocytes (IEC) and next activate 
NFkB, type I interferon and other inflammatory pathways. This leads to production of pro-inflammatory (TNF, IL-1β, IL-6, IFN, 
IL-17, etc), and anti-inflammatory (primarily IL-10) cytokines and chemokines that will next activate innate lymphocytic cells and 
other immune cells and the immune system in general.81 82 There is some support for such a mechanism in chronic inflammatory 
disease, including findings of high amounts of sulfate-reducing bacteria in patients with UC77 83; an association between the 
highest tertile of carbohydrate-restricted diet and RA, in a nested case–control study among 386 individuals who developed 
RA and 1886 matched controls from the Swedish Västerbotten Intervention Program cohort with prospectively sampled dietary 
survey84; association of high-fibre intake with low risk of Crohn’s disease among 170 776 participants from the prospective 
Nurses’ Health Study I23; association of high intake of red meat and total protein and risk of developing inflammatory 
polyarthritis in the population-based prospective cohort of 25 630 participants from the European Prospective Investigation 
of Cancer in Norfolk.35 Finally, a prospective study of 191 patients with UC in remission found that high consumption of meat, 
particularly red and processed meat, protein and alcohol was associated with risk of relapse, and that high sulfur or sulfate 
intakes may offer an explanation for the observed findings.85 Additionally, support of the notation that diet may affect systemic 
immune response is provided by the finding that intake of low glycaemic index diet was found to lower secretion of TNF and 
IL-6 from stimulated peripheral blood mononuclear cells from obese humans.86 (Right) Intake of high fibre and low meat may 
promote an effective mucosal barrier and support the effects of outcome after drug targeting the pro-inflammatory molecule 
TNF (TNF inhibitors). Intake of soluble plant fibre has been found to block bacterial adhesion to gut enterocytes in animal and 
cell studies.87 The genetic architecture of the individual may also impact the influence of lifestyle factors.15 Hence, to provide 
lifestyle recommendations, we need to understand the effects of lifestyle on the immune system and how lifestyle may improve 
the therapeutic outcome and reduce the need of medical treatment in the individual person. Information on diet and non-diet 
lifestyle exposures may be collected by using, for example, questionnaires and lifestyle-associated biomarkers or a combination 
of these methods.88–90 Evidence-based biomarkers for lifestyle assessment are scarce91–111 and mostly used for studies on 
healthy individuals.112–115 IEC, intestinal epithelial cells; IL, interleukin; MAMPS, microbial-associated molecular patterns; NFkB, 
nuclear factor kappa B; RA, rheumatoid arthritis; TLR, Toll-like receptors; TNF, tumour necrosis factor; UC, ulcerative colitis.
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Patient characteristics and eligibility criteria
Inclusion criteria: patients ≥18 years with CID who 
are beginning TNFi therapy, who have not previously 
received TNFi treatment and who are able to read and 
understand Danish. Exclusion criteria: patients who have 
previously received a biological treatment and patients 
who by virtue of illiteracy or cognitive impairment are 
unable to complete the questionnaire.
Clinical data (table 1) will include personal data, data 
on health and disease, dietary and non-dietary lifestyle 
information, laboratory measurements and disease 
activity scores including patient-reported outcome 
measures (PROMs), clinical assessments and laboratory 
data. Participants will complete validated questionnaires 
on disease activity, quality of life and lifestyle using an 
electronic link. Studies have revealed electronic question-
naires to be comparable to paper based in relation to the 
outcomes (ie, PROMs).42 43
Primary and secondary endpoints
Primary endpoint
The predefined primary endpoint will be the proportion 
of patients with a clinical response to therapy 14–16 weeks 
after treatment initiation. Below are the disease-specific 
definitions of clinical response to therapy:
 ► Crohn’s disease: clinical remission, defined as 
Harvey-Bradshaw Index (HBI) of 4 or less;44
 ► Ulcerative colitis: clinical remission, defined as Mayo 
Clinic Score of 2 or less (with no individual subscore 
of >1);45
 ► rheumatoid arthritis: clinical response, defined as at 
least a 20% improvement according to the criteria of 
the American College of Rheumatology (ACR20);46
 ► axial spondyloarthritis: clinical response, defined as 
at least a 20% improvement according to the Assess-
ment of Spondyloarthritis International Society 
(ASAS20);47 48
 ► psoriatic arthritis: clinical response, defined as at 
least a 20% improvement according to the criteria of 
ACR20;49
 ► psoriasis: clinical response, defined as at least a 75% 
improvement in Psoriasis Area and Severity Index 
(PASI 75);50
 ► hidradenitis suppurativa: clinical response, defined as 
at least a 50% reduction in the abscess and inflam-
matory-nodule count, with no increase in abscess or 
draining-fistula counts (HiSCR response);51
 ► non-infectious uveitis: clinical response, defined as 
those who did not have a treatment failure (treatment 
failure will be based on assessment of new inflam-
matory lesions, best-corrected visual acuity, anterior 
chamber cell grade and vitreous haze grade).52
Key secondary outcomes
Major secondary outcomes, also to be measured 14–16 
weeks after treatment initiation, include disease-spe-
cific outcome measures that cover core outcome sets, 
the generic health-related quality of life (HRQoL) and 
disability at endpoint. Below are a list of disease-specific 
secondary outcomes.
 ► CD: Selecting Therapeutic Targets in Inflamma-
tory Bowel Disease (STRIDE; abdominal pain, diar-
rhoea, altered bowel habit, SES-CD (presence of 
ulcers, ulcerated surface, affected surface, presence 
of narrowing, number of affected segments), altera-
tions of cross-sectional imaging (MR, CT, ultrasound) 
(only when endoscopy cannot adequately evaluate 
inflammation)), HBI (general well-being, abdom-
inal pain, number of liquid stools per day, abdom-
inal mass, extraintestinal manifestations (abscess, 
fistulas, fissures, arthralgia, uveitis, erythema 
nodosum, pyoderma gangrenosum, mouth ulcers)), 
physician global assessment, number of draining 
fistulas, corticosteroid-free remission, concomitant 
medication.
 ► UC: STRIDE (rectal bleeding, altered bowel habit, 
endoscopic remission (Mayo endoscopic subscore 
of 0–1)), Mayo Clinical Score (Mayo endoscopic 
subscore, stools, rectal bleeding, physician global 
assessment), Mayo ‘normal mucosal appearance’, 
Mayo clinical response, Simple Clinical Colitis Activity 
Index (bowel frequency (day), bowel frequency 
(night), urgency of defecation, blood in stool, general 
well-being, extracolonic features), physician global 
assessment, corticosteroid-free remission, concomi-
tant medication.
 ► RA: Tender joints, swollen joints, pain, physician 
global assessment, patient global assessment, Health 
Assessment Questionnaire (HAQ), C reactive protein 
(CRP), Disease Activity Score (DAS)28-CRP, Simpli-
fied Disease Activity Index (SDAI).
 ► Axial spondyloarthropathy: Bath Ankylosing Spon-
dylitis Metrology Index (BASMI), Bath Ankylosing 
Spondylitis Functional Index (BASFI), Bath Anky-
losing Spondylitis DAI, total score for back pain, 
physician global assessment, patient global assess-
ment, CRP.
 ► Psoriatic arthritis: tender joints, swollen joints, psori-
atic arthritis pain, physician global assessment, patient 
global assessment, HAQ-DI, CRP, DAS28-CRP, SDAI, 
PASI.
 ► Psoriasis: PASI, physician global assessment, patient 
global assessment, psoriatic arthritis pain, Derma-
tology Life Quality Index total score.
 ► Hidradenitis suppurativa: percentage of participants 
who achieve abscess and inflammatory nodule (AN) 
count of 0, 1 and 2, respectively, patient’s global assess-
ment of skin pain, modified Sartorius score.
 ► Non-infectious uveitis: new active, inflammatory chori-
oretinal or retinal vascular lesions relative to baseline, 
inability to achieve ≤0.5+ or a two-step increase rela-
tive to the best state achieved at all visits in anterior 
chamber cell grade or vitreous haze grade, worsening 
of best-corrected visual acuity by ≥15 letters relative to 
best state achieved.
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Table 1 Collection of patient characteristics, outcome measures and explanatory variables   
Variable Pre Week 14–16
Clinical data*
  Gender (F, M) X
  Age (years) X
  Diagnosis (disease) X
  Onset of diagnosis (year)† X
  Education (level)‡ X
  Menopause (year) X
  Comorbidity (diseases, Charlson index) X
  Medication (predefined choices) X X
  Diet (FFQ) (predefined choices) X
  Changes in diet (predefined choices) X
  Non-dietary lifestyle factors‡ (predefined choices) X X
Investigations:
  Height (cm) X
  Weight (kg) X X
   Body mass index (kg/m2) X X
  Routine blood analyses§ X X
  Endoscopy¶ X X
Biological samples**
  Fasting blood samples X X
  Faeces samples X X
  Urine samples X X
  Biopsies¶ X X
CD
  Disease location (predefined choices) X
  Prior operations (y/n, description) X
  Disease behaviour (fistulising, luminal) X
  Perianal involvement (y/n) X
  STRIDE—(y/n) NA X
   Abdominal pain (y/n) X X
   Diarrhoea (y/n) X X
   Altered bowel habit (y/n) X X
   SES-CD (score) X X
    Presence of ulcers (score) X X
    Ulcerated surface (score) X X
    Affected surface (score) X X
    Presence of narrowing (score) X X
    Number of affected segments (score) X X
   Alterations of cross-sectional imaging (MR, CT, UL) (y/n)†† X X
  HBI index (score) X X
  HBI of 4 or less (y/n)‡‡ X X
   General well-being (score) X X
   Abdominal pain (score) X X
   No of liquid stools per day (N) X X
Continued
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Variable Pre Week 14–16
   Abdominal mass (score) X X
   Manifestations (abscess, fistulas, fissures, arthralgia, uveitis, erythema nodosum, 
pyoderma gangrenosum, mouth ulcers, one point for each) (N)
X X
  Physician global assessment (score) X X
  Physician global assessment (0–100 mm VAS) X X
  Patient global assessment (0–100 mm VAS) X X
  Corticosteroid-free remission§§ (y/n) X
  Concomitant medication (y/n, predefined choices) X X
  Number of draining fistulas (fistulising CD) X X
UC
  Disease location (predefined choices) X
  Prior operations (y/n, description) X
  STRIDE criteria (y/n) NA X
   Rectal bleeding (y/n) X X
   Altered bowel habit (y/n) X X
   Endoscopic remission (Mayo endoscopic subscore of 0–1) X X
  Mayo clinical score of 2 or less with no individual subscore of >1‡‡ X X
  Mayo ‘normal mucosal appearance’ (y/n) X X
  Mayo clinical response§§ (y/n)¶¶ X X
  Mayo clinical score (score) X X
   Mayo endoscopic subscore (score) X X
   Stools (score) X X
   Rectal bleeding (score) X X
   Physician global assessment (score) X X
  SCCAI (score) X X
   Bowel frequency (day) (score) X X
   Bowel frequency (night) (score) X X
   Urgency of defecation (score) X X
   Blood in stool (score) X X
   General well-being (score) X X
   Extracolonic features (one per manifestation) X X
  Physician global assessment (0–100 mm VAS) X X
  Patient global assessment (0–100 mm VAS) X X
  Corticosteroid-free remission§§ (y/n) X
  Concomitant medication (y/n, predefined choices) X X
Rheumatoid arthritis
  Positive for anti-CCP/RF (y/n) X
  Swollen joint count (of 28/66 joints examined) X X
  Tender joint count (of 28/68 joints examined) X X
  DAS28-CRP (score) X X
  SDAI (score) X X
  ACR20 (y/n)‡‡ NA X
  ACR50 (y/n) NA X
  ACR70 (y/n) NA X
Table 1 Continued 
Continued
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Variable Pre Week 14–16
  EULAR good or moderate response  
(y/n)
NA X
  Low disease activity (DAS28<3.2) NA X
  DAS28 remission (DAS28<2.6) NA X
  Physician global assessment (0–100 mm VAS) X X
  Patient global assessment (0–100 mm VAS) X X
  Patient assessment of pain (0–100 mm VAS) X X
  HAQ (score) X X
axSpA
  Positive for HLA-B27 (y/n) X
  BASDAI (score) X X
  BASFI (score) X X
  BASMI (score)
  Total score for back pain (0–100 mm VAS) X X
  Patient global assessment of disease activity  
(0–100 mm VAS)
X X
  Patient assessment of pain (0–100 mm VAS) X X
  Physician global assessment (0–100 mm VAS) X X
  ASAS20 (y/n)‡‡ NA X
  ASAS40 (y/n) NA X
  ASAS partial response (y/n) NA X
  ASAS5/6 response (y/n) NA X
PsA
  Dactylitis (y/n) X X
  Enthesitis (y/n) X X
  PASI (score) X X
  PASI 75 response (y/n) NA X
  PASI 90 response (y/n) NA X
  ACR20†† NA X
  Swollen joint count (of 28/66 joints examined) X X
  Tender joint count (of 28/68 joints examined) X X
  DAS28-CRP (score) X X
  Patient global assessment of disease activity (0–100 mm VAS) X X
  Patient assessment of PsA pain (0–100 mm VAS) X X
  Physician global assessment (0–100 mm VAS) X X
  SDAI X X
  HAQ (score) X X
PsO
  Psoriatic arthritis (y/n) X X
  PASI (score) X X
  PASI75 response (y/n)‡‡ NA X
  PASI90 response (y/n) NA X
  Patient global assessment of disease activity (0–100 mm VAS) X X
  Patient assessment of PsA pain (0–100 mm VAS) X X
  Physician global assessment (0–100 mm VAS) X X
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Variable Pre Week 14–16
  DLQI (score) X X
Hidradenitis suppurativa
  HiSCR response‡‡ NA X
  Hurley stage*** (score) X X
  Previous systemic treatment (y/n, description) X
  Prior surgery (y/n, description) X
  Lesion counts (N) X X
  Total no. of abscesses and inflammatory nodules (N) X X
  No. of abscesses (N) X X
  No. of inflammatory nodules (N) X X
  No. of draining fistulas (N) X X
  Modified Sartorius score (score) X X
  Percentage of participants who achieve abscess and inflammatory nodule (AN) count of 0, 
1 and 2, respectively
X X
  Patient global assessment of skin pain (score) X X
  DLQI (score) X X
NiU
  SUN (score) X X
  Uveitis treatment failure (y/n)‡‡ NA X
  New active, inflammatory chorioretinal or retinal vascular lesions relative to baseline (y/n) X X
  Inability to achieve ≤0.5+  or a two-step increase relative to best state achieved at all visits 
in anterior chamber cell grade or vitreous haze grade (y/n)
X X
  Worsening of best-corrected visual acuity by ≥15 letters relative to best state achieved (y/n) X X
Health-related quality of life††† X X
  SF12 (score) X X
  SHS (score) X X
  Physician global assessment (0–100 mm VAS) X X
  Patient global assessment (0–100 mm VAS) X X
  Rome-III (score) X X
  NYHA (score) X X
  Continuation of anti-TNF treatment (y/n, predefined choices for stopping if no) X X
Adverse events
  Discontinuation due to adverse events (y/n) X
  Serious adverse event (y/n) X
   Death (y/n) X
   Occurrence of surgery (y/n) X
   Occurrence of hospital admission (y/n) X
  Occurrence of disease-related complication (y/n) X
Laboratory§
  CRP (mg/L)‡‡‡ X X
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Exploratory secondary (tertiary) outcomes
Additional exploratory outcomes will include biolog-
ical measures, disease-specific disease activity measures 
as individual measure and combined scores as well 
as changes of these (including those measured by 
physician/patients such as patients’ health-related 
quality of life) at first clinical follow up53 (week 
14–16) (table 1). Other outcomes include changes in 
the use of concomitant medication, achievement of 
steroid-free remission, serious adverse events such as 
Variable Pre Week 14–16
*Data will be collected using a questionnaire as well as local and national registries.
†Registry data will be retrieved from the Danish registries using the Danish individual civil registration number (CPR) 
including BIO-IBD,116 DANBIO,117 DERMBIO118 (database on IBD, RA, HS, axSpA, PsA and PsO patients on biological 
therapy), the National Patient Registry (eg, comorbidity), registries on medication and use of receipts, local laboratory 
databases (laboratory data) and the electronic patient records (side effects).
‡Lifestyle (dietary and non-dietary) will be registered using a validated FFQ that includes food items and a photographic 
food atlas of picture series of portion sizes will be used to assess intake of food groups, such as meat and dairy, and 
calculate total energy, fibre, protein, fat, sugar and carbohydrate intakes as well as glycaemic index and load. In addition, 
questions on non-diet lifestyle factors (smoking, physical activity, alcohol consumption and use of over-the-counter 
medicine (use of probiotics, prebiotics, painkillers, laxative and antidiarrhoea agents)) as well as educational level and year 
of menopause (female) are included.63 The follow-up questionnaire is identical to the initial questionnaire apart from the 
questions on food items that only contain questions on changes of diet since the last questionnaire.
§Routine blood analyses include CRP, haemoglobin, erythrocyte count, haematocrit, erythrocyte mean cell volume, mean 
cell haemoglobin and mean cell haemoglobin concentration, leucocyte count, differential count, thrombocytes, K+, Na+, 
creatinine, coagulation factor II+VII+X, alanine aminotransferase, alkaline phosphatase, gamma-glutamyl transferase, 
haemoglobin glycation, lipids (cholesterol, high-density, low-density cholesterol) and transglutaminase.
¶Only patients with IBD.
**From all participants, blood, urine and faeces are sampled. In addition, from patients with IBD, intestinal biopsies are 
sampled. In selected cases, the additional biological material on participants from this study may be retrieved from the 
Patobank and the Danish Biobank. The samples will be collected adhering to the Sample PRE-analytical Code and 
Biospecimen Reporting for Improved Study Quality guidelines, using standard operational procedures describing and 
logging primary container, centrifugation conditions, centrifugation parameters and storage conditions.120 121 The biological 
material will be stored at Odense Patient data Explorative Network (OPEN) (biological material from Odense University 
Hospital) or at SHS (biological material from the other hospitals).
††Only patients with CD when endoscopy cannot adequately evaluate inflammation.
‡‡Primary endpoint for the individual diseases
§§Corticosteroid-free remission. Clinical remission in patients using oral corticosteroids at baseline (pre) that have 
discontinued corticosteroids and in clinical remission at first follow-up.
¶¶A reduction in complete Mayo score of ≥3 points and ≥30% from baseline (or a partial Mayo score of ≥2 points and 
≥25% from baseline, if the complete Mayo score was not performed at the visit) with an accompanying decrease in rectal 
bleeding subscore of ≥1 point or absolute rectal bleeding subscore of ≤1 point.
***Data for the Hurley stage reflect actual assessment. A patient’s overall Hurley stage is the highest stage across all 
affected anatomical sites. Stage I is defined as the localised formation of single or multiple abscesses without sinus tracts 
or scarring, stage II as recurrent abscesses (single or multiple) with sinus tract formation and scarring and stage III as 
multiple abscesses with extensive, interconnected sinus tracts and scarring.
†††All participants will be asked whether they have any complaints regarding or are known with diseases affecting the 
bowel, the skin, rheumatic complaints and so on, and if no to both questions they will not be asked to complete the 
relevant questionnaire.
‡‡‡Biological response defined as a drop in CRP level of more than 25% or to the normal level among patients with an 
elevated CRP before treatment (higher than normal range).119
ACR, American College of Rheumatology; ASAS, Assessment of Spondyloarthritis International Society; axSpA, axial 
spondyloarthropathy; BASDAI, Bath Ankylosing Spondylitis Disease Activity Index; BASFI, Bath Ankylosing Spondylitis 
Functional Index; BASMI, Bath Ankylosing Spondylitis Metrology Index; CCP/RF, cyclic citrullinated peptide/rheumatoid 
factor; CD, Crohn’s disease; CRP, C-reactive protein; DAS, Disease Activity Score; DLQI, Dermatology Life Quality 
Index; EULAR, European League Against Rheumatism; FFQ, Food Frequency Questionnaire; HAQ, Health Assessment 
Questionnaire; HBI, Harvey-Bradshaw Index; HiSCR, Hidradenitis Suppurativa Clinical Response; HLA-B27, human 
leucocyte antigen; IBD, inflammatory bowel disease; K+, potassium; NA, not applicable; N+ sodium; NiU, non-infectious 
uveitis; NYHA, New York Heart Association; PASI, Psoriasis Area and Severity Index; PsA, psoriatic arthritis; PsO, psoriasis; 
SCCAI, Simple Clinical Colitis Activity Index; SDAI, Simplified Disease Activity Index; SES-CD, Simple Endoscopic Score 
for Crohn’s Disease; SF12, Short Form Health Survey; SHS, Short Health Scale; STRIDE, Selecting Therapeutic Targets 
in Inflammatory Bowel Disease; SUN, Standardization of Uveitis Nomenclature for Reporting Clinical Data; TNF, tumour 
necrosis factor; UC, ulcerative colitis; UL, ultrasound; VAS, Visual Analogue Scale; y/n, yes/no.
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hospitalisation and the need for surgery at first clinical 
follow-up (table 1).53
Prognostic factors
Primary exposure variable
For the primary prognostic model, the primary exposure 
variables will be prioritised in the following order:
 ► The upper tertile of the sample (33.3% of the total 
sample), based on the ratio of fibre to meat intake, is 
associated with better treatment outcomes.
 ► The lower tertile of the sample (33.3% of the total 
sample) with respect to intake of red and processed 
meat and the upper tertile of the sample (33.3% of 
the total sample) with respect to intake of dietary 
fibres are independently associated with better treat-
ment outcomes, and a potential interaction between 
them may further improve treatment outcomes.
Other (exploratory) exposure variables
 ► other lifestyle factors independently or combined 
(red and processed meat intake, vegetable intake, 
dietary fibre intake, cereal intake, gluten consump-
tion, legume intake, red wine consumption, dairy 
product intake, amount of physical activity, smoking 
status, total protein/fat, protein/fat from red and 
processed meat, glycaemic index);
 ► pretreatment lifestyle-associated biomarkers;
 ► combinations of lifestyle factors and lifestyle-associ-
ated biomarkers;
 ► gene–environment interaction analyses;
 ► pretreatment levels of inflammatory molecules.
data management
The electronic questionnaire is in Danish. Participants 
will access the questionnaire by an electronic link which 
will be sent to their personal, electronic mailbox. All data 
will be stored in a secure research storage facility.54 Infor-
mation registered by clinicians and technicians will peri-
odically be transferred from paper format to electronic 
format using either double entry of data or automated 
forms processing.55
No patient risks are foreseen as a direct result of this 
project. Clinicians will treat enrolled patients in the same 
fashion as non-enrolled patients. As a consequence, no 
data monitoring committee will be established.
statistical methods
Prognostic factor research was developed to aid health-
care providers in estimating the probability or risk that a 
specific event will occur in the future. Hence, it has the 
potential to inform clinical decision-making.56 Concep-
tually, a good prognostic model is one that functions 
for patients other than those from whom the data was 
derived.57 Our intention is to use data obtained from this 
rigorously designed, prospective cohort study to explore 
our ability to predict clinical response across specific CID 
conditions (Y=primary endpoint) and to explore whether 
diets high in fibre AND low in red and processed meat 
(X=assessed at baseline) are an informative prognostic 
factor. Per default, the statistical models will include the 
specific CID condition and the clinical centre as fixed 
effects. Specific details will be part of the final statis-
tical analysis plan (SAP). In terms of transparency, when 
reporting the multivariable models, the study will adhere 
to guidelines from the ‘Transparent Reporting of a multi-
variable prediction model for Individual Prognosis or 
Diagnosis’.
Sample size considerations
Deciding sample size is a well-known difficulty with 
exploratory prognostic factor research studies. To obtain 
an adequate number of outcome events, we apply ‘the 
rule of thumb’, whereby 10 outcomes are needed for 
each independent variable. We plan to enrol 320 patients 
in total and we anticipate that 50% of these will experi-
ence a clinical response during the 14–16 weeks period 
after TNFi initiation.1 With this in mind, and anticipating 
that we will see at least 160 events (ie, clinical response 
among the 320 patients), the study is sufficiently powered 
to explore the impact of as many as 16 independent 
variables including condition and clinical centre. Since 
using the ‘rule of thumb’ method to justify sample size 
is a debated practice, we went one step further and esti-
mated the statistical power to detect differences between 
two dietary groups. For the contrast between groups and 
for a comparison of two independent binomial propor-
tions (those with high-fibre and low-meat intake vs other) 
using Pearson’s χ2 statistic, with a χ2 approximation, with 
a two-sided significance level of 0.05 (P<0.05), a total 
sample size of 318—assuming an ‘allocation ratio’ of 1 
to 2 (one-third)—has an approximate power of 0.924 
(ie, >90% statistical power) if the anticipated proportions 
responding are 60% and 40%, respectively.
Statistical programming will be done using the software 
SAS V.9.4(SAS Institute Inc., Cary, NC, USA), STATA or 
R, with transparent reporting of the source code used 
to analyse the data. Computational details will be avail-
able in the prespecified SAP. These will be finalised 
before data collection is complete. Our primary analysis 
set will be based on observations available at the time of 
study closure. In other words, we will consider ‘Data as 
observed’ to be our primary resource for statistical infer-
ence. However, for the purpose of sensitivity, multiple 
sensitivity analyses will be performed to assess the robust-
ness of the primary analyses, including analyses based on 
the ‘Non-responder-imputation’ and multiple-imputation 
analyses, which are based on model-based approaches for 
missing data (these details will be available in the final 
SAP). A simplistic ‘null responder imputation’ would 
represent a conservative base case and is likely valid even 
if data is ‘missing not at random’,58 as it assumes, and 
implies that patients have not improved or have worsened 
after entering the study.
No interim analyses will be performed. All reported 
P values will be two sided, and by default, these will not 
be adjusted for multiple comparisons. However, due to 
potential issues of multiplicity, as multiple statistical tests 
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will be performed in the study, we will interpret ‘statisti-
cally significant’ findings in the context of whether the 
95% CI excludes outcomes that could be perceived as 
clinically important. We will use the following consistent 
language to describe effects that might appear as chance 
findings: “The prognostic factor appears to have little or 
no effect on the clinical outcome if the point estimate 
or the boundaries of the 95% CI lies between 0.80 and 
1.25”. Thus, despite an apparently statistically significant 
finding (P<0.05), a relative point estimate within the 
range of 0.80 and 1.25 will not be considered a clinically 
meaningful effect.
The Food Frequency Questionnaire (FFQ) we use in 
the present study has been widely used in prospective 
cohort studies, including in European prospective investi-
gations in the fields of oncology and chronic diseases.59 60 
It has been extensively used and evaluated in the Danish 
population, and results from different methods demon-
strate consistency.61 62 However, the FFQ is not without 
limits, in particular with respect to the lack of informa-
tion on portion sizes.63 64 We, therefore, modified the 
FFQ to capture information on portion size.63 A second 
potential limitation relates to comprehensive question-
naire completion. However, in a pilot study of 10 hospital 
patients (50–70 years of age) the FFQ was completed 
within 40–50 min and no complaints were reported. 
The imprecision of the FFQ will lead to large CIs. The 
result will most likely lead to null results (rather than 
type 2 errors). The disease groups are expected to vary 
in several aspects such as age, gender and body mass 
index. We will, however, be unable to determine the 
potential effect of selective diet reporting on responders 
and non-responders.65 On the other hand, studies have 
suggested that dietary patterns are relatively stable among 
adults in the Danish population.66 Due to study design 
and the limited number of participants, this study may 
not capture every lifestyle difference between responders 
and non-responders. Similarly, this study has only limited 
power to detect gene–environment interactions. To avoid 
potential type 2 errors, it is important that the results 
are replicated in other well-characterised patient popu-
lations using prospectively sampled dietary information. 
To further evaluate the robustness of the results, study 
results would preferably be replicated in cohorts from 
other countries.
Project organisation
The study team is organised into three significant 
groups: a clinical research group (CRG), an analyt-
ical research group (ARG) (figure 2) and a steering 
committee (SC). The CRG includes specialists from 
gastroenterology, rheumatology, dermatology and 
ophthalmology who will be implicated in the clinical 
care and assessment of study participants. The ARG 
will be responsible for performing laboratory analyses 
on the collected biological material. Finally, the SC—
whose members include Professor Uffe Holmskov, 
Professor Jens Kjeldsen, Professor Torkell Ellingsen and 
Professor Vibeke Andersen—are responsible for plan-
ning and organising the study within the appropriate 
legal framework, facilitating meetings for the three 
study groups and for scientific follow-up. The group as 
a whole, including clinicians and analysts, is responsible 
for the scientific results and budget.
Collaboration between patients and health profes-
sionals on research projects is a relatively new 
Figure 2 Organisation and patient research partners. IBD, inflammatory bowel disease.
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phenomenon.67–69 The involvement of patients in 
research (patient research partners (PRPs)) will ideally 
will give a stronger voice to patients’ views on research, 
specifically with respect to research priorities. Further-
more, individual patients and patient organisations can 
contribute to research study design, preparing educa-
tional material, discussing results, disseminating results 
and recruiting study participants. Recommendations 
on incorporating PRPs into research study processes 
suggest that they should be provided with relevant 
support and education. With this initiative, we were 
keen to gain experience with PRPs. Thus, this project 
was built with input from the Danish Colitis-Crohn’s 
Association, represented by its director Charlotte Lind-
gaard Nielsen, the Danish Psoriasis Association, repre-
sented by its director Lars Werner and three individual 
patients with RA from one of the participating clinical 
departments.
The SC will hold telephone conferences every 
2–4 weeks, but more often when necessary, and face-to-
face meetings 3–4 times per year. Among participants, the 
SC will organise telephone conferences every 2–4 weeks, 
again more often when necessary, and face-to-face meet-
ings at the time of enrolment and every year thereafter 
until the conclusion of the study.
Perspectives
The use of prognosis research evidence at multiple stages 
is central to the process of translational research, with 
the ultimate goal of improving patient outcomes. Prog-
nosis research includes various aspects of importance to 
healthcare professionals, enabling them to guide indi-
vidual patients in terms of shared decision-making via 
overall prognosis, knowledge on important prognostic 
factors or models and subsequently (from randomised 
trial evidence) stratified medicine.56 70–72 We anticipate 
that BELIEVE study will reveal prognostic factors of 
importance, including whether the diet of the patient is 
likely to interfere with the outcome of being prescribed 
a TNFi treatment. Hopefully, by combining various 
phenotype and genotype aspects into the prognostic 
models, BELIEVE study will add value to the long-term 
goal of achieving ‘personalised medicine’.
We will seek to replicate findings that are identified 
as having prognostic value in other prospective cohorts, 
including from a planned study of CID cases from the 
Danish ‘Diet, Health and Cancer’ cohort and potentially 
from other cohorts with lifestyle data.73 74
dissemination of results to the public and scientifically
The target journal for the primary outcome will be a 
general medical journal directed at family physicians. 
Family physicians see patients with CID across the entire 
spectrum of disease. Moreover, lifestyle recommenda-
tions are an important element of general practice. 
Hence, although family physicians are not necessarily 
the primary decision-makers with respect to treatment 
of patients with CID, a role more ably assumed by 
specialists, they have considerable influence on lifestyle 
decisions for patients with CID. Subsequently, other 
hypotheses will be analysed and manuscripts prepared 
(independent of findings), with the intention of 
submitting additional articles to specialised journals in 
the areas of nutrition, immunology, gastroenterology, 
rheumatology, dermatology and ophthalmology.
Authorship confers credit and has important academic, 
social and financial implications and therefore any 
authorship on manuscripts coming from BELIEVE study 
is associated with responsibility and accountability for the 
published work. Thus, we intend to follow the recom-
mendations of the International Committee of Medical 
Journal Editors (ICMJE) to ensure that contributors who 
have made substantive intellectual contributions to a 
paper are given credit as authors, but also that contrib-
utors credited as authors understand their role in taking 
responsibility and being accountable for the published 
work.
The ICMJE criteria for authorship was designed to 
distinguish authors from other contributors based on 
the following four criteria: (1) substantial contributions 
to the conception or design of the work; or the acquisi-
tion, analysis or interpretation of data for the work; (2) 
drafting the work or revising it critically for important 
intellectual content; (3) final approval of the version 
to be published and (4) agreement to be accountable 
for all aspects of the work in ensuring that questions 
related to the accuracy or integrity of any part of the 
work are appropriately investigated and resolved.
In addition to the scientific reporting of results, major 
findings with translational implications will be commu-
nicated to health professionals, patient organisations, 
public health policy-makers and to the general public 
through various media and news activities.
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